Plastic model of the human insulin molecule

Visual Science created the plastic model of the human insulin analog Deguldec. This hexameric protein is a long-acting medicine, which is developed by pharmacological company Novo Nordisc, the world leader in the drug design in the sphere of diabetes therapy.

This model played a part of the symbolic first stone during the ceremonial start of construction of the brand new Novo Nordisc insulin drug factory near Kaluga, Russian Federation.

Insulin Degludec, Novo Nordisk
From the left to the right: The Ambassador Extraordinary and Plenipotentiary of Denmark to the Russian Federation, T.R. Jensen; The Governor of the Kaluga region, A.D. Artamonov, the President of the Novo Nordisk company A/S, L.R. Sorensen; the Vice-president of the Novo Nordisk company A/S, S.V. Smirnov.

Novo Nordisc is planning to invest over $100 million into the factory. The first production of it should appear in 2 years time.